TEST:

clonoSEQ

Patients with myeloma, learn from @bdermanmd as he discusses MRD in multiple myeloma in patient-friendly language. https://t.co/iQOXGZrO8v #mmsm clonoSEQ is FDA-cleared to assess MRD in MM, CLL and B-ALL. For further info & test limitations: https://t.co/sE39cuZxFD (@clonoSEQ)

Myeloma patients, join @theMMRF ‘s webinar on minimal (aka measurable) residual disease or #MRD ft. @bdermanmd & @Rfonsi1. https://t.co/hcedfDYGhw #mmsm clonoSEQ is FDA-cleared to assess MRD in MM, CLL and B-ALL. For further info & test limitations: https://t.co/sE39cuZxFD (@clonoSEQ)

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry [Actual Study Start Date: Oct 13, 2020] PI = @JmPagelMD @AdaptiveBiotech https://t.co/XZKO6nFRjT #NCT04545333 #mmMRD #mmsm #ALLsm #CLLsm #lymsm ()

** How to interpret MRD results reporting below LOD ** Finding a 0 (zero) result in the clonoSEQ assay is great. But sometimes a patient has a result of "Residual sequences detected at below (the) level of detection (LOD)" What does this mean? 1/x #mmsm (@Rfonsi1)

million dollar question? CR conventionally or Clonoseq One size doesnt fit all but if in real CR than personally i would wait for Car-T ( but no harm with referal and getting deck chairs lined up ) We all have seen that unlike Lymphoma , Car-T doesnt seem to have a plateau in MM (@BijoyTelivala)

Why this study is imp.? Patchy involvement of #myeloma raises concern that BM MRD may miss active disease. However, does that still hold with highly sensitive tests e.g. EuroFlow/ClonoSEQ? (Listen to @BloodCancerTalk where @End_myeloma spoke about this➡️https://t.co/qyeMiJ9dQi) ()

Important paper on ClonoSEQ MRD and PET/CT concordance at day#100 post-ASCT in #Myeloma @Rfonsi1 #mmsm 🧵 https://t.co/WrBIP9mmm5 ()

Study by @NicholasShortMD on adult ALL patients shows 39% of patients are MRD- by MFC at 10⁻⁴, who are MRD+ by MFC at 10⁻⁶. https://t.co/KgrGE2964S #leusm clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: https://t.co/sE39cv05vb ()

Pre-transplant MRD discordance in 39% of cases comparing BCR/ABL RT-PCR vs ClonoSeq NGS in ALL (p190 and p210). Worse outcomes for NGS positive. So interesting! Dekker, et al. 128 #Tandem23 #Leusm #BMTsm ()

‘@bdermanmd in #MRD2STOP asks questions “to see if patients who have sustained MRD positivity may actually benefit from escalation of therapy.” https://t.co/ibl2flPzlF clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: https://t.co/sE39cv05vb ()

Watch @bdermanmd as he covers #MRD2STOP, which was presented at #ASH22. https://t.co/A68CqG9870 #mmsm clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: https://t.co/sE39cuZxFD ()

A scenario for the myeloma-inclined: 65 y/o pt who is 4 years post-2nd transplant & on KPd since. At 2 years, MRD testing showed 43/million (clonoSEQ); at 3 years, 38/mil (i.e., no change). I think of this as 'detante' btwn disease & therapy. Would you ever de-escalate? #mmMRD ()

"We loved @end_myeloma ‘s #ASH22 updates on MASTER: impressive outcomes for standard risk pts and pts w/ 1 HRCA. Ultra-high risk pts (2+ HRCA) will be addressed in MASTER 2. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: https://t.co/sE39cv05vb" (@clonoSEQ)

Our rockstar fellow ⁦@AlexandraRezMD⁩ presenting our data using clonoSEQ MRD testing as surveillance in mantle cell lymphoma at #ASH22 . Great job!👏 ()

We are testing the sensitivity and specificity of a non-invasive approach to MRD by combining WB-DW MRI with Peripheral Blood clonoSEQ #mmsm https://t.co/XSxPvWcZ8m ()

We are excited to see the #ASH22 data! clonoSEQ is FDA-cleared to assess MRD in CLL, MM and B-ALL. For further info: https://t.co/sE39cv05vb ()

#LLMCongress2022 #leusm Jabbour: MRD monitoring with NGS (@clonoSEQ) better prognostic measure than flow based MRD. Blin treatment for MRD is SOC based on BLAST trial data, but needs further optimization to determine when alloHCT can be avoided. ()

Reasonable treatment order. I will also suggest a baseline Clonoseq testing for clonality.Both CLL and myeloma can be followed. ()

Yes in theory. Would need 2 separate specimens (and not a decalcified BMBx), one which is predom “CLL” and one which is predom “MM”. You can do clonoSEQ ID test on both and do comparative clonality analysis ()

Join us next week at #AVMC2022 The American Virtual Myeloma Conference | Tuesday, September 20 | Chaired by @JoshuaRichterMD Free registrations for HCPs https://t.co/BTCYyvay1w #oncologyprofessionals #hematology #hcps #myeloma @clonoSEQ @sanofi ()

#EHA22 #leusm Jabbour: NGS (ClonoSEQ) being explored by MDACC in frontline therapy (hCVAD or mCVD/Ino) using banked samples. ()

"Is MRD ready for prime time? It is past due!" says #myeloma expert @Rfonsi1 in this article. #mmsm https://t.co/r4pUvdIWOV clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuZxFD ()

Listen to the @ACCCBuzz Podcast ft. @Rfonsi1 & Dr. Graf on MRD for pts with #myeloma or #CLL: https://t.co/uMcLbWKd0h #mmsm clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/eQNnO8Er0X ()

Read about early myeloma screening, by @IreneGhobrial and Dr. Lanny Kirsch. https://t.co/R480v2hzWn clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuZxFD ()